Financial calendar

Interim report Q3 2019: October 22 2019

Year-end report 2019: February 11 2020

Idogen develops tolerogenic cell therapy – individualised treatment for each patient

Idogen AB   |   Medicon Village   |   Scheelevägen 2   |   SE-223 81 Lund   |  Sweden   |  E-mail: info at idogen dot com

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.